Erasmus School of Health Policy & Management
Associate professor | Health Technology Assessment (HTA)
- blommestein@eshpm.eur.nl
- Room
- J8-23
- Location
- Burg. Oudlaan 50, Rotterdam
More information
Work
- M. R. Seefat, D. G.J. Cucchi, K. Groen, M. L. Donker, K. G. van der Hem, M. Westerman, A. M. Gerrits, A. Beeker, N. W.C.J. van de Donk, H. M. Blommestein & S. Zweegman (2024) - Treatment sequences and drug costs from diagnosis to death in multiple myeloma - European Journal of Haematology, 112 (3), 360-366 - doi: 10.1111/ejh.14119 - [link]
- Marianne Luyendijk, Agnes Jager, Sanne M. Buijs, Sabine Siesling, Carin A.Uyl de Groot & Hedwig M. Blommestein (2023) - Cost-Effectiveness Analysis of MammaPrint<sup>®</sup> to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer - PharmacoEconomics, 41 (8), 981-997 - doi: 10.1007/s40273-023-01277-4 - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
- Christine Bennink, Hans Westgeest, Daan Schoonen, Femke Boersen, Pieter Sonneveld, Jan Hazelzet, Hedwig Blommestein & Marjolein Van Der Klift (2023) - High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study - HemaSphere, 7 (6) - doi: 10.1097/HS9.0000000000000913 - [link]
- Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H.J.T. de Hingh, Frank J.P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G.E. de Vries, Carin A. Uyl-de Groot & Sabine Siesling (2023) - Changes in survival in de novo metastatic cancer in an era of new medicines - Journal of the National Cancer Institute, 115 (6), 628-635 - doi: 10.1093/jnci/djad020 - [link]
- Lj Bakker, Fw Thielen, Wk Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
- Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager (2023) - Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - JAMA network open, 6 (2) - doi: 10.1001/jamanetworkopen.2022.56170 - [link]
- Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W.M. Martens, Saskia M. Wilting, Carin Uyl-de Groot & Agnes Jager (2023) - Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs? - Breast Cancer: Targets and Therapy, 15, 147-161 - doi: 10.2147/BCTT.S387375 - [link]
- Yi Hsuan Chen, Hedwig M. Blommestein, Reinder Klazenga, Carin Uyl-de Groot & Marco van Vulpen (2023) - Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands - Cancers, 15 (2) - doi: 10.3390/cancers15020516 - [link]
- Christine Bennink, Marjolein van der Klift, Pieter Sonneveld, Jan A. Hazelzet & Hedwig M. Blommestein (2022) - High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records - Health Policy and Technology, 11 (4) - doi: 10.1016/j.hlpt.2022.100695 - [link]
Health Technology Assessment
- Year Level
- master, master, master
- Year
- 2023
- Course Code
- GW4546M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4555M
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year Level
- master
- Year
- 2023
- Course Code
- GW4585M
Master Thesis HE
- Year Level
- master, master
- Year
- 2023
- Course Code
- GW4592M
Master HEPL-HE 2023-2024
- Year
- 2023
- Course Code
- GWMTTHEPL